Expanding Market Focus Avinger is actively developing new product applications for coronary artery disease, opening opportunities to offer cutting-edge image-guided solutions for the large and underserved CAD market. Business development efforts can target cardiology clinics and hospitals seeking minimally invasive intervention tools.

Recent Funding Growth With recent injections of funding totaling over 21 million dollars, including a 15 million dollar expansion and a 5.3 million dollar raise, Avinger is poised for further product development and market expansion. This indicates substantial growth investment, making their innovative vascular devices a promising sales opportunity.

Innovative Product Launches The company recently launched the Tigereye ST CTO crossing device and conducted a limited release at prominent clinical centers, demonstrating a focus on advancing and validating new technology. Targeting vascular specialists and interventional cardiologists familiar with CTO crossing devices could lead to strategic sales.

Strategic Industry Position Operating within a competitive landscape of large healthcare firms like Medtronic and Boston Scientific, Avinger’s unique lumivascular platform and image-guided systems present distinctive selling points. Partners and clients looking for specialized, minimally invasive therapies are potential key targets for growth.

Technology Adoption Avinger utilizes advanced tech stacks including React, Salesforce, and Cloudflare, alongside proprietary image-guided catheter systems. Engaging with hospitals and clinics seeking innovative vascular intervention tools that leverage latest technological advancements offers strong sales potential.